New uses of cd133 plasmid

Abstract

The invention provides new application of CD133 plasmid. The CD133 plasmid can be effectively used for enhancing the in-vitro killing effect of DC-CIK on breast cancer stem cells.

Description

technical field [0001] The present invention relates to a new application of CD133 plasmid. Background technique [0002] Breast cancer is the most common malignancy in women worldwide. A large number of evidences show that it is the existence of breast cancer stem cells (Breast Cancer Stem Cell, BCSC) that leads to its easy metastasis, recurrence and resistance to radiotherapy and chemotherapy. Adoptive cell immunotherapy (ACI), which has emerged in recent years, is a new therapy for tumors that are insensitive to radiotherapy and chemotherapy. It has broad clinical prospects and has received more and more attention. [0003] The existence of CSC is one of the most important factors affecting the treatment effect and prognosis of breast cancer. The current clinical radiotherapy and chemotherapy can only eliminate common breast cancer cells, while the remaining BCSCs that are resistant to radiotherapy and chemotherapy can still proliferate continuously, leading to breast ca...

AI Technical Summary

Problems solved by technology

[0003] The existence of CSC is one of the most important factors affecting the treatment effect and prognosis of breast cancer. The current clinical radiotherapy and chemotherapy can only eliminate common breast cancer cells, while the remaining BCSCs that are resistant to radiotherapy and chemotherapy can continue to proliferate, leading to breast cancer. Recurrence and metastasis, so finding an effective way to kill CSC has become a new direction for breast cancer treatment

Images